ERBB2 and breast carcinoma: In the NA-PHER2 study, 30 ER-positive and HER2-positive breast cancers were treated with 18 weeks of trastuzumab and pertuzumab, combined with fulvestrant and palbociclib and were assessed for pCR (ypT0/is/N0) [22].